Dianthus Therapeutics, Inc. (DNTH)
Health Care ยท Pharmaceutical Preparations
Dianthus Therapeutics, Inc. (DNTH) is listed on Nasdaq, where its shares have traded since September 12, 2023. SentiSense covers Dianthus Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Marino Garcia is its chief executive officer. The company reports 92 employees, and its corporate website is www.dianthustx.com.
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Latest reported results
Dianthus Therapeutics reported revenue of $1.2 million for Q3 FY2026, up 205.6% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 262 institutions reported holding DNTH, with 65.8 million shares worth $6.4 billion in aggregate. The largest reported holders were FMR, T. Rowe Price and BlackRock. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on DNTH
- DNTH sentiment: whether news and social coverage of Dianthus Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- DNTH ownership: all 262 reporting institutions, plus insider and congressional trades.
- DNTH financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Dianthus Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Dianthus Therapeutics, Inc. do?
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases.
What sector is DNTH in?
SentiSense classifies Dianthus Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does DNTH stock trade?
Dianthus Therapeutics, Inc. (DNTH) is listed on Nasdaq, where its shares have traded since September 12, 2023.
Who is the CEO of Dianthus Therapeutics, Inc.?
Marino Garcia is the chief executive officer of Dianthus Therapeutics, Inc..